SCM Pharma will launch formulation development services following the acquisition of new facilities through a collaboration with the University of Sunderland. SCM Pharma’s preclinical capability will be housed in the formulation and analytical labs at the University of Sunderland’s new science complex. The launch follows a two-year development project with Mitovie Pharma, under which SCM provides formulation support for one of its four lead candidates.

Michael Hawthorne, chief executive officer at Mitovie Pharma, said, “Like SCM Pharma, we generally deal with more complex and challenging products. This is why we have been working closely with their team to help fast-track the development of one of our key products. The knowledge acquired by SCM Pharma during this formulation process will be vital in helping us quickly tech transfer our product into clinical trials manufacturing within their cGMP production facility.”
Initially, SCM will provide developmental services for liquid formulations, including emulsions and suspensions for parenteral, oral and topical administration using either proprietary or customers’ novel delivery systems. Stability and analytical testing support services will also be provided along with GMP formulation.

Dianne Sharp, managing director at SCM Pharma, said, “This is a huge milestone for our business and what better stages than ICSE and AAPS to simultaneously launch this core new service to the European and North American markets. With our track record of consistently supplying products for clinical trials and niche commercial markets, we can now support clients from start to finish, which means lower tech transfer costs, quicker time to market and our personable service throughout the process.”

The new service will be formally launched at ICSE in October.